immatics biotechnologies GmbH announced that its phase 2 trial with IMA910 in patients with advanced colorectal cancer (CRC) showed significantly longer overall survival in comparison to a matched-pair analysis of patients from the recently published phase 3 MRC COIN trial. The immatics study also showed that patients who developed immune responses to two or more of the tumor associated peptides (TUMAPs) in IMA910 correlate with longer overall survival times. These data were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting.
IMA910 is a cancer vaccine comprising 13 rationally selected TUMAPs identified directly from primary colorectal tumor tissue.
The IMA910 phase 2 study recruited 92 patients with advanced/metastatic CRC who had shown no progression following 12 weeks of first line oxaliplatin-based chemotherapy and who were on a planned break from their chemotherapy regimen.
The overall survival in IMA910 treated patients was compared to patients enrolled in one arm (C) of the MRC COIN trial using a pre-planned independent results-blinded matched-pair analysis. In common with the IMA910 patients, patients in the C arm of the COIN study had also shown no progression following 12 weeks of first line oxaliplatin-based chemotherapy and were on a planned break from the intermittent chemotherapy regimen set out in the study protocol. The independent, blind, matched-pair analysis was carried out to eliminate potential differences in baseline characteristics and prognostic factors and to provide a near identical population for the study’s overall survival analysis. The COIN trial, which recruited close to 2,500 patients, is the largest study to-date in patients with advanced CRC and was designed to assess the relative benefits of three different treatment regimens one of which involved the use of intermittent chemotherapy treatment.
In the immatics’ phase 2 study, patients treated with IMA910 had a median survival of 19.7 months compared to the 16.5 months median survival seen in the matched patients from the COIN study when following from the start of first-line chemotherapy. The Hazard Ratio (HR) was 0.665 (p=0.0386). The patients treated with IMA910 also had higher one year (69% versus 55%) and two year (40% versus 24%) survival rates.
Release Date: June 1, 2012
Source: immatics biotechnologies GmbH
Filed Under: Drug Discovery
